TrioBiotics Pharma AG
Triton BioPharma establishes Fellowship Program
Triton Biopharma AG / Strategic Company Decision Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- ZUG, Switzerland – February 13th, 2009 – TRITON BIOPHARMA AG (Frankfurt: 4ON) today announced that its wholly owned subsidiary, Triton BioPharma LLC, has founded a Fellowship Program in support of valuable graduate program research. A Triton Fellowship Program was established to provide supplemental financial assistance to promising predoctoral students with innovative projects of potential significance in the area of human heath and drug discovery and development. A total of USD $51,000 was recently awarded under Triton’s Fellowship Program, which included recipients in the graduate program at The University of Mississippi, School of Pharmacy. Triton established the Fellowship Program in response to a growing need for external funding to subsidize meaningful pharmaceutical and biotechnological research conducted in academic laboratories. The goal of this program is to fund new and ongoing projects that may have commercial or industrial importance in the advancement of new treatments for a variety of disease conditions. 'Triton is committed to building partnerships with academic laboratories, as leaders in innovative research and development', said Angelo Boujos, Chairman and CEO of Triton BioPharma AG. Mr. Boujos continued, 'We have been impressed with the new discoveries and investigations emerging in academic programs and believe that industrial support is essential to create novel and innovative treatments for human disease as well as bringing these innovations to market.' About Triton BioPharma AG Triton BioPharma AG is a holding company and is only active through its wholly-owned subsidiaries, Triton BioPharma SARL and Triton BioPharma LLC. These subsidiary companies are responsible for all of Triton’s biotechnology operations and R&D activities in the discovery, development, and commercialization of novel drug leads from marine sources for the global market. With a commitment to cooperation in innovation, Triton brings together a significant network of international collaborators, consultants and industry specialists in the areas of microbiology, pharmacology, synthetic and organic chemistry, marine natural products and biochemistry. Accessing this critical mass of scientific experts and utilizing research facilities worldwide is a principal component of its drug discovery and development strategy. Triton’s current pipeline includes advanced preclinical candidates in the treatment of neuropsychiatric disorders, including depression and anxiety, inflammation, infectious diseases and cancer. The company was founded in 2008 and has its corporate office in Toronto, Canada. For more information, visit www.tritonbiopharma.com Contact: Investor Relations Europe: Milestone Media AG, Zug (Switzerland) Phone: +41 (0) 41 5000 769 Fax: +41 (0) 41 5000 728 E-mail: info@milestonemedia.ch 13.02.2009 Financial News transmitted by DGAP ----------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found